Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tanreqing Capsules is a Traditional Chinese Medicine (TCM) product developed by Shanghai Kaibao Pharmaceutical, primarily used for treating respiratory conditions such as community-acquired pneumonia (CAP) and acute bronchitis. The formulation is an oral version of the well-known Tanreqing Injection and consists of five key ingredients: *Scutellaria baicalensis* (Huangqin), Bear Bile Powder (Xiongdanfen), Goat Horn (Shanyangjiao), *Lonicera japonica* (Jinyinhua), and *Forsythia suspensa* (Lianqiao). It is indicated for patients exhibiting "phlegm-heat obstructing lung syndrome," characterized by fever, cough, and yellow sputum. Pharmacologically, it demonstrates anti-inflammatory, antiviral, and antibacterial activities, often serving as an adjunct to conventional antibiotic therapy to improve clinical recovery rates and reduce symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tanreqing Capsules.